The phenomenon of hemoglobin variability with erythropoiesis stimulating agents in renal transplant patients

Clinical Nephrology

Volumn 72, Issue 4, 2009, Pages 292-297

  Fernandez Fresnedo G ^a   de Francisco, A L M ^a   Alamillo, C Gomez ^a   Ruiz, J C ^a   Rodrigo, E ^a   Arias, M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Erythropoiesis stimulating agents; Hemoglobin variability; Renal transplant

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CREATININE; HEMOGLOBIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RAPAMYCIN; STEROID;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; ERYTHROPOIESIS; FEMALE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY FUNCTION; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; RENAL GRAFT DYSFUNCTION; SURVIVAL RATE;

EID: 70350359133     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp72292     Document Type: Article

References (23)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined Phase I and II clinical trial. N Engl J Med. 1987; 316: 73.
2. US Renal Data Silstem. USRDS 2001 Annual Report. Bethesda, MD: National Institute of Health, 2001 (http://www.usrds.org/ailas.htm),
3. Fernández Fresnedo G, Palomar R, Rodrigo E et al. Prevalence of anemia in renal transplant patients: results from MOST, an observational trial. Transplant Proc. 2005; 37: 3821.
4. Vanrenterghem Y, Ponticelli C, Morales JM et al. Prevalence and management of anemia in renal transplant recipients: a European Survey. Am J Transplant. 2003; 3: 835.
5. Locatelli F, Aljama P, Barany P et al. European Best Practice Guidelines Working Group. Revised european best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004; 19 (Suppl. 2): ii1.
6. Fishbane S, Berns JS. Evidence and implications of hemoglobin cycling in anemia management. Nephrol Dial Transplant. 2007; 22: 2129.
7. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003; 1: 111.
8. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int, 2005; 68:137.
9. Aguera-Morales M, Macdougall I. Hemoglobin variability in renal transplant recipients: more or less than in dialysis patients. Nephrol Dial Transplant. 2007; 22 (Suppl 6): 0400(a).
10. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anemia in patients with chronic renal failure, Nephrol Dial Transplant. 2004; 19 (Suppl 2): ii1.
11. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target hemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet. 2007; 369: 381.
12. Ofsthun N, Labrecque J, Lacson E, Keem M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney hit. 2003; 63: 1908.
13. Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease in adults. Am J Kidney Dis. 2006; 47: S16.
14. Kawaguchi T, Moriyama T, Suzuki K et al. Pilot study ofthe optimum hematocrit for patients in the predialysis stage after renal transplantation. Transplant Proc. 2004; 36: 1293.
15. Ortiz F, Guirado L, Diaz J et al. Use of recombinant human erythropoietin in kidney transplant patients with stable graft function. Transplant Proc. 2003:35:1767.
16. Berns JS, Fishbane S. Hemoglobin variability: random fluctuation, epipbenomenon, or phenomenon? Semin Dial. 2006; 19: 257.
17. Berns JS, Elzein H, Lynn RI et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003; 64: 514.
18. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soe Nephrol. 2006; 1: 1205.
19. BaranyP Carrero JJ, Jonsdottir SS et al. Variability of Hb level in relation to inflammatory status and iron metabolism in hemodialysis patients. J Am Soc Neprol. 2007; 17: 580A.
20. Mueller HJ, Hahn K, Schneider HW et al. Contributing factors to Hb-cycling in a large cohort of ESRD patients in Germany. J Am Soc Nephrol. 2007; 17: 579.
21. Feldman HI, Brunelli SM, Joffe MM et al. Causal analysis of hemoglobin variability and mortality among dialysis patients. J Am Soc Nephrol. 2006; 17: 583.
22. Gilbertson DT, Ebben JP, Bradbury B et al. The effect of Hb variability and trends on mortality. J Am Soc Neprol. 2007; 17: 582.
23. Ishani A, Guo H, Gilbertson DT et al. Time to target hemoglobin concentration (11 g/dl)-risk of hospitalization and mortality among incident dialysis patients. Nephrol Dial Transplant. 2007; 22: 2247.